| scholarly article | Q13442814 |
| P50 | author | Jürgen Müller | Q73864435 |
| P2093 | author name string | Ming Zhou | |
| Deborah K Morrison | |||
| Kun Ping Lu | |||
| Timothy D Veenstra | |||
| Thomas P Conrads | |||
| Xiao Zhen Zhou | |||
| Michele K Dougherty | |||
| Terry D Copeland | |||
| Daniel A Ritt | |||
| P433 | issue | 2 | |
| P921 | main subject | phosphorylation | Q242736 |
| P304 | page(s) | 215-224 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | Regulation of Raf-1 by direct feedback phosphorylation | |
| P478 | volume | 17 |
| Q38220879 | "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway |
| Q37112466 | (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway |
| Q39576677 | 5'-Nitro-indirubinoxime inhibits epidermal growth factor- and phorbol ester-induced AP-1 activity and cell transformation through inhibition of phosphorylation of Pin1. |
| Q36958464 | 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells |
| Q38296404 | A MAPK-positive feedback mechanism for BLR1 signaling propels retinoic acid-triggered differentiation and cell cycle arrest |
| Q43543397 | A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal |
| Q46111608 | A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer |
| Q35692123 | A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells |
| Q35829995 | A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis |
| Q33606991 | A common biological mechanism in cancer and Alzheimer's disease? |
| Q37510558 | A computationally engineered RAS rheostat reveals RAS-ERK signaling dynamics |
| Q28541015 | A functional screen reveals an extensive layer of transcriptional and splicing control underlying RAS/MAPK signaling in Drosophila |
| Q28485362 | A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease |
| Q34468902 | A mathematical model of CR3/TLR2 crosstalk in the context of Francisella tularensis infection |
| Q35826693 | A novel role for copper in Ras/mitogen-activated protein kinase signaling |
| Q24319503 | A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity |
| Q41210920 | A step forward for patients with NRAS-mutant melanoma |
| Q33413060 | A-RAF kinase functions in ARF6 regulated endocytic membrane traffic |
| Q33802003 | ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks |
| Q42321002 | ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q50292949 | Activated MAPK phosphorylates RAF1 |
| Q38743591 | Activation kinetics of RAF protein in the ternary complex of RAF, RAS-GTP, and kinase on the plasma membrane of living cells: single-molecule imaging analysis |
| Q34507257 | Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis |
| Q30429122 | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial |
| Q52684503 | Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. |
| Q37142816 | Allosteric proteins as logarithmic sensors |
| Q38696684 | An Interdisciplinary Approach for Designing Kinetic Models of the Ras/MAPK Signaling Pathway. |
| Q28396530 | Arsenite and insulin exhibit opposing effects on epidermal growth factor receptor and keratinocyte proliferative potential |
| Q85793877 | Association between PIN1 promoter polymorphisms and risk of nasopharyngeal carcinoma |
| Q40106302 | B- and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding |
| Q40347847 | B-Raf and C-Raf signaling investigated in a simplified model of the mitogenic kinase cascade |
| Q48086875 | B-Raf is critical for MAPK activation during mitosis and is regulated in an M phase-dependent manner in Xenopus egg extracts |
| Q36973111 | BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition |
| Q38281838 | BRAF inhibitors: experience in thyroid cancer and general review of toxicity |
| Q36732681 | BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines |
| Q34374407 | BRAFV600E negatively regulates the AKT pathway in melanoma cell lines |
| Q47322668 | Bach1 is critical for the transformation of mouse embryonic fibroblasts by Ras(V12) and maintains ERK signaling |
| Q49583955 | Bidirectional alteration of Cav-1 expression is associated with mitogenic conversion of its function in gastric tumor progression |
| Q92089548 | Biofunctionalized Materials Featuring Feedforward and Feedback Circuits Exemplified by the Detection of Botulinum Toxin A |
| Q41848152 | Biology using engineering tools: the negative feedback amplifier |
| Q51969062 | Bistable MAP kinase activity: a plausible mechanism contributing to maintenance of late long-term potentiation. |
| Q38854172 | C-Raf is required for the initiation of lung cancer by K-Ras(G12D). |
| Q34438059 | Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback |
| Q34648711 | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression |
| Q52655309 | Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. |
| Q24597152 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma |
| Q42370777 | Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors |
| Q47123785 | Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems |
| Q42495304 | Comparative analysis of enzyme activities and mRNA levels of peptidyl prolyl cis/trans isomerases in various organs of wild type and Pin1-/- mice |
| Q48439138 | Comparative evaluation of reverse engineering gene regulatory networks with relevance networks, graphical gaussian models and bayesian networks. |
| Q30425261 | Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer |
| Q34361161 | Complexity of receptor tyrosine kinase signal processing |
| Q38238604 | Consequences of feedback in signal transduction for targeted therapies. |
| Q35547898 | Dentate Gyrus Development Requires ERK Activity to Maintain Progenitor Population and MAPK Pathway Feedback Regulation |
| Q48240280 | Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. |
| Q41208231 | Development of a tandem affinity phosphoproteomic method with motif selectivity and its application in analysis of signal transduction networks |
| Q42683550 | Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization. |
| Q28301932 | Differential regulation and properties of MAPKs |
| Q24674150 | Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms |
| Q94686204 | Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study |
| Q39712781 | Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. |
| Q50336648 | Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation |
| Q24652600 | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity |
| Q24294914 | Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors |
| Q90211585 | Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling |
| Q90670689 | Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling |
| Q41412772 | Divergent effects of intrinsically active MEK variants on developmental Ras signaling |
| Q37598950 | Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling |
| Q40281543 | Dynamic positive feedback phosphorylation of mixed lineage kinase 3 by JNK reversibly regulates its distribution to Triton-soluble domains |
| Q39561513 | ERK and PDE4 cooperate to induce RAF isoform switching in melanoma |
| Q35967605 | ERK1/2 can feedback-regulate cellular MEK1/2 levels. |
| Q38329529 | Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines |
| Q36640274 | Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling |
| Q37404768 | Effects of butyltins on mitogen-activated-protein kinase kinase kinase and Ras activity in human natural killer cells |
| Q37588717 | Emerging Raf inhibitors. |
| Q33971120 | Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity |
| Q33737298 | Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways |
| Q52725941 | Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes. |
| Q92755864 | Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial-Mesenchymal Transition in Cancer |
| Q37831109 | Feedback regulation of EGFR signalling: decision making by early and delayed loops. |
| Q27342077 | Fibroblast growth factor receptor 1 signaling in adult cardiomyocytes increases contractility and results in a hypertrophic cardiomyopathy |
| Q45715391 | Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs |
| Q30586789 | Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals |
| Q41885536 | GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation |
| Q42660143 | Gene regulatory network reconstruction by Bayesian integration of prior knowledge and/or different experimental conditions |
| Q38333462 | Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein. |
| Q36128637 | Glutaminolysis Was Induced by TGF-β1 through PP2Ac Regulated Raf-MEK-ERK Signaling in Endothelial Cells |
| Q89498248 | Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers |
| Q43470663 | How blocking Raf activates the MAPK pathway |
| Q39367513 | Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk |
| Q28648013 | Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding |
| Q34407252 | Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase |
| Q37154463 | Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics. |
| Q33613978 | Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling |
| Q90469263 | Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition |
| Q35785759 | Inference of regulatory networks with a convergence improved MCMC sampler |
| Q38504413 | Influence of Prior Knowledge in Constraint-Based Learning of Gene Regulatory Networks |
| Q39298876 | Inhibition of MEK pathway in vestibular schwannoma cell culture |
| Q50075745 | Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit |
| Q92512121 | Inhibition of peptidyl-prolyl isomerase (PIN1) and BRAF signaling to target melanoma |
| Q41792391 | Integrated RAS signaling defined by parallel NMR detection of effectors and regulators. |
| Q34800432 | Integrating Bayesian variable selection with Modular Response Analysis to infer biochemical network topology |
| Q33761415 | Interaction with Shc prevents aberrant Erk activation in the absence of extracellular stimuli |
| Q36318172 | Involvement of PP2A in viral and cellular transformation |
| Q33809881 | Isoproterenol and cAMP block ERK phosphorylation and enhance [Ca2+]i increases and oxygen consumption by muscarinic receptor stimulation in rat parotid and submandibular acinar cells |
| Q38065119 | It takes two to tango--signalling by dimeric Raf kinases |
| Q46551389 | Juglone inactivates cysteine-rich proteins required for progression through mitosis |
| Q34491748 | Kidins220/ARMS binds to the B cell antigen receptor and regulates B cell development and activation |
| Q34156491 | Knockdown of mitogen-activated protein kinase (MAPK) signalling in the midgut of Anopheles stephensi mosquitoes using antisense morpholinos |
| Q33467308 | Learning robust cell signalling models from high throughput proteomic data |
| Q28476446 | Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics |
| Q27853310 | Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression |
| Q29615542 | MAP kinase signalling pathways in cancer |
| Q26771192 | MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy |
| Q36717848 | MEK-1 activates C-Raf through a Ras-independent mechanism |
| Q38591835 | MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road |
| Q36328021 | MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms |
| Q64281299 | Mapping connections in signaling networks with ambiguous modularity |
| Q42626658 | Mathematical and computational analysis of adaptation via feedback inhibition in signal transduction pathways |
| Q38197024 | Mechanism and consequences of RAF kinase activation by small-molecule inhibitors |
| Q35693850 | Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma |
| Q47739142 | Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. |
| Q34341768 | Mechanisms of GnRH-induced extracellular signal-regulated kinase nuclear localization |
| Q38007869 | Mechanisms of acquired resistance to ERK1/2 pathway inhibitors |
| Q60928825 | Mechanisms shaping the role of ERK1/2 in cellular senescence (Review) |
| Q37785803 | Mechanistic principles of RAF kinase signaling |
| Q33698718 | Melanoma epidemiology, biology and prognosis |
| Q36930517 | Models from experiments: combinatorial drug perturbations of cancer cells |
| Q39164873 | Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. |
| Q92630701 | Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art |
| Q36862768 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response |
| Q48318714 | Negative Feedback Regulation of Raf/MEK/ERK Cascade After Sublethal Cerebral Ischemia in the Rat Hippocampus |
| Q45317149 | Negative feedback regulation of MAPK pathway |
| Q28079202 | Negative feedback regulation of the ERK1/2 MAPK pathway |
| Q45317147 | Negative regulation of MAPK pathway |
| Q39240086 | Neighboring phosphoSer-Pro motifs in the undefined domain of IRAK1 impart bivalent advantage for Pin1 binding |
| Q30277214 | Network Architecture Predisposes an Enzyme to Either Pharmacologic or Genetic Targeting |
| Q52666594 | New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. |
| Q64104874 | Oncogenic Hijacking of the PIN1 Signaling Network |
| Q44943773 | Oncogenic β-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. |
| Q34303057 | Oscillations in MAPK cascade triggered by two distinct designs of coupled positive and negative feedback loops |
| Q51747038 | Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. |
| Q36490557 | PAK1 is a novel MEK-independent raf target controlling expression of the IAP survivin in M-CSF-mediated osteoclast survival |
| Q92002846 | PIN1 Provides Dynamic Control of MYC in Response to Extrinsic Signals |
| Q53561253 | PIN1, the cell cycle and cancer. |
| Q24322118 | PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma |
| Q50292953 | PP2A dephosphorylates RAF1 |
| Q24310359 | PTPIP51, a novel 14-3-3 binding protein, regulates cell morphology and motility via Raf-ERK pathway |
| Q36490565 | Pathway crosstalk between Ras/Raf and PI3K in promotion of M-CSF-induced MEK/ERK-mediated osteoclast survival |
| Q37891181 | Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease |
| Q37295744 | Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. |
| Q33690728 | Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity. |
| Q28248256 | Phosphorylation-specific prolyl isomerization: is there an underlying theme? |
| Q24684898 | Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism? |
| Q36347245 | Pin1 inhibits PP2A-mediated Rb dephosphorylation in regulation of cell cycle and S-phase DNA damage |
| Q34353633 | Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis |
| Q30365214 | Pin1: a molecular orchestrator in the heart. |
| Q39804200 | Plasma membrane nanoswitches generate high-fidelity Ras signal transduction |
| Q35539933 | Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control |
| Q46458312 | Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites |
| Q40359711 | Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes |
| Q33858319 | Proinflammatory stem cell signaling in cardiac ischemia |
| Q28249249 | Prolyl cis-trans isomerization as a molecular timer |
| Q26825421 | Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins |
| Q27024695 | Prolyl isomerase Pin1 in cancer |
| Q37076842 | Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability |
| Q37656270 | Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. |
| Q42152409 | Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling |
| Q91162949 | Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway |
| Q36689092 | Proteomic applications of protein quantification by isotope-dilution mass spectrometry. |
| Q24299553 | Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells |
| Q39935235 | Pulsatile and sustained gonadotropin-releasing hormone (GnRH) receptor signaling: does the ERK signaling pathway decode GnRH pulse frequency? |
| Q38720684 | Quantification of growth factor signaling and pathway cross talk by live-cell imaging |
| Q35888647 | Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling |
| Q35070321 | Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma |
| Q47144509 | RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition |
| Q90197668 | RAF kinases are stabilized and required for dendritic cell differentiation and function |
| Q28289378 | RAF protein-serine/threonine kinases: Structure and regulation |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q39647630 | RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells |
| Q30433106 | RSK in tumorigenesis: connections to steroid signaling |
| Q28271724 | RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation |
| Q24316181 | Raf family kinases: old dogs have learned new tricks |
| Q28565091 | Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation |
| Q28237793 | Raf kinases in cancer-roles and therapeutic opportunities |
| Q36002845 | Raf kinases: function, regulation and role in human cancer |
| Q42562424 | Raf-independent, PP2A-dependent MEK activation in response to ERK silencing |
| Q27692653 | Raf-interactome in tuning the complexity and diversity of Raf function |
| Q30493239 | Rapid and sustained nuclear-cytoplasmic ERK oscillations induced by epidermal growth factor |
| Q37062789 | Ras nanoclusters: combining digital and analog signaling |
| Q29614734 | Ras, PI(3)K and mTOR signalling controls tumour cell growth |
| Q49874520 | Ras-Mediated Activation of the Raf Family Kinases |
| Q47256544 | Reciprocal regulation of PPARγ and RUNX2 activities in marrow mesenchymal stem cells: Fine balance between p38 MAPK and Protein Phosphatase 5. |
| Q28580581 | Regulation and role of Raf-1/B-Raf heterodimerization |
| Q39980994 | Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor. |
| Q40286524 | Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1. |
| Q38439535 | Regulation of RAF protein kinases in ERK signalling |
| Q28572621 | Regulation of cardiac hypertrophic signaling by prolyl isomerase Pin1 |
| Q28577191 | Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5 |
| Q24303940 | Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas |
| Q28541382 | Robustness and evolvability of the human signaling network |
| Q35823006 | Role of LRP1 and ERK and cAMP Signaling Pathways in Lactoferrin-Induced Lipolysis in Mature Rat Adipocytes |
| Q36819381 | Role of mitogen-activated protein kinase kinase kinases in signal integration |
| Q35834035 | Roles of Prolyl Isomerases in RNA-Mediated Gene Expression |
| Q34966603 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q92859810 | SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics |
| Q92642505 | SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers |
| Q35941359 | Scaffold proteins confer diverse regulatory properties to protein kinase cascades. |
| Q24304936 | Second nature: biological functions of the Raf-1 "kinase" |
| Q39139352 | Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation |
| Q38798084 | Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives |
| Q36471372 | Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. |
| Q39537040 | Signal integration and coincidence detection in the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) cascade: concomitant activation of receptor tyrosine kinases and of LRP-1 leads to sustained ERK phosphorylation via dow |
| Q33623159 | Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters |
| Q58714835 | Signaling pathways as linear transmitters |
| Q30497330 | Signalling ballet in space and time |
| Q26795609 | Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance |
| Q41908921 | Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase |
| Q35571550 | Site-specific, intramolecular cross-linking of Pin1 active site residues by the lipid electrophile 4-oxo-2-nonenal |
| Q37583522 | Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1. |
| Q36276136 | Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf |
| Q39406388 | Specifically targeting ERK1 or ERK2 kills melanoma cells |
| Q35848373 | Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells |
| Q38585847 | Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. |
| Q41322187 | Stimulus-induced uncoupling of extracellular signal-regulated kinase phosphorylation from nuclear localization is dependent on docking domain interactions |
| Q39173195 | Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations |
| Q39536250 | Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. |
| Q39350519 | Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine |
| Q37301884 | Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging |
| Q36716462 | System properties of ErbB receptor signaling for the understanding of cancer progression |
| Q30497351 | Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. |
| Q54512822 | TPA-induced cell transformation provokes a complex formation between Pin1 and 90 kDa ribosomal protein S6 kinase 2. |
| Q54119124 | Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway. |
| Q92663940 | Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy |
| Q91632717 | Targeting Alterations in the RAF-MEK Pathway |
| Q38272894 | Targeting RAS-ERK signalling in cancer: promises and challenges |
| Q42020468 | Targeting oncogenic BRAF in human cancer |
| Q33823577 | Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. |
| Q50026949 | Targeting the MAPK Pathway in RAS Mutant Cancers |
| Q47279988 | Targeting the Raf kinases in human cancer: the Raf dimer dilemma |
| Q92115553 | Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling |
| Q37753517 | Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response |
| Q34981046 | The -842G/C polymorphisms of PIN1 contributes to cancer risk: a meta-analysis of 10 case-control studies |
| Q51013762 | The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. |
| Q36260506 | The ERK cascade: a prototype of MAPK signaling |
| Q36052399 | The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and |
| Q37102628 | The PP2C Alphabet is a negative regulator of stress-activated protein kinase signaling in Drosophila. |
| Q21629049 | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner |
| Q24337165 | The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1 |
| Q36421433 | The SH3 domain of Lck modulates T-cell receptor-dependent activation of extracellular signal-regulated kinase through activation of Raf-1. |
| Q34648135 | The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells |
| Q38212717 | The clinical development of MEK inhibitors |
| Q34572036 | The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells |
| Q37686994 | The importance of Raf dimerization in cell signaling |
| Q38852028 | The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target |
| Q51328396 | The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells. |
| Q34519801 | The molecular scaffold kinase suppressor of Ras 1 is a modifier of RasV12-induced and replicative senescence |
| Q36945537 | The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease |
| Q44785984 | The prolyl isomerase Pin1 interacts with and downregulates the activity of AMPK leading to induction of tumorigenicity of hepatocarcinoma cells |
| Q34125273 | The prolyl isomerase Pin1 modulates development of CD8+ cDC in mice |
| Q28273385 | The prolyl isomerase Pin1 targets stem-loop binding protein (SLBP) to dissociate the SLBP-histone mRNA complex linking histone mRNA decay with SLBP ubiquitination |
| Q38740000 | The renewed battle against RAS-mutant cancers |
| Q38939954 | The role of Pin1 in the development and treatment of cancer |
| Q36804492 | The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer |
| Q37773788 | The role of signaling pathways in the development and treatment of hepatocellular carcinoma |
| Q35826480 | The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence |
| Q33668293 | Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions |
| Q38716887 | Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. |
| Q33323383 | Topological analysis of MAPK cascade for kinetic ErbB signaling |
| Q47256372 | Transcriptionally inducible Pleckstrin homology-like domain family A member 1 attenuates ErbB receptor activity by inhibiting receptor oligomerization. |
| Q35030861 | Transcriptome-based analysis of mitogen-activated protein kinase cascades in the rice response to Xanthomonas oryzae infection. |
| Q38160738 | Tumor adaptation and resistance to RAF inhibitors |
| Q42811739 | Tyrosine phosphorylation and Ras activation is required for hydrogen peroxide-mediated Raf-1 kinase activation |
| Q34341432 | Ultradian oscillations and pulses: coordinating cellular responses and cell fate decisions |
| Q28276886 | Vemurafenib: the first drug approved for BRAF-mutant cancer |
Search more.